Dendreon Corporation

  DNDN website

DNDN   /  Message Board  /  Read Message

 


 








ced17
charolais1966
green228
investor737
mij3000
pgh27106
ralphla54
speculative_striker
TFRingo
The_HJW
tweets
white78nite



My DNDN Ignore List


Open Search


Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  282968 of 369092  at  6/10/2009 3:03:59 PM  by

swells

ASM Recap

I just returned home from the ASM (only seven miles). I don't see any other posts yet, so I'll jump in with my impressions.

First, I'll give the sequence of the meeting.

1. Brief welcome by Gold.

2. Formal part of the meeting conducted by Brewer. Took all of 10 to 15 minutes. Everybody reading from a script. All four proposals passed.

3. Powerpoint presentation by Gold. Nothing new in the slides. As he said at the beginning, he would be brief, because he figured most of the attendees had already seen the presentation, perhaps several times.

4. Q & A with Gold. Took about 45 minutes.

Overall, not much of significance occurred during the Q & A for anyone who is a regular reader of the IV board. Pretty much everything that was said is already known. Here's what I think are the key points.

1. The executive team and the board are committed to growing Dendreon as an independent company. Stated several times by Gold and once by Brewer. I didn't sense any reason not to take them at their word. That said, Gold did make sure to state that the board does have a fiduciary responsibility to consider any acquisition offers seriously. Also, he refused to state whether Dendreon had been approached by anyone for an acquisition.

2. Reiterated that Dendreon will be partnering with someone for ROW rights to Provenge. No timeframe given or indications as to the current state of any discussions.

3. NJ Facility is being built out to capacity. Looking at additional facilities for the future.

4. BLA submission will be in the fourth quarter. FDA will respond within six months of submission.

5. Analyst meeting is this summer. Stated more than once, and very definitely chose not to narrow down the timeframe to other than "this summer".

6. Pricing will not be announced until after approval.

My overall impression is that Dendreon is much more concerned with getting the path to Provenge commercialization "right" rather than "quick". they seem intent on taking a very methodical approach to the whole process.

That's it from me,

Steve

P.S. I'm sure some of the other attendees will be chiming in later today or tomorrow.




 
     e-mail to a friend      printer-friendly     add post to library      
| More
Recs: 169  |  Views: 1191
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
282969 Re: ASM Recap grr 9 6/10/2009 3:08:58 PM
282973 Re: ASM Recap eagleeyeinvestor 11 6/10/2009 3:18:50 PM
282975 Re: ASM Recap jeep 6/10/2009 3:25:08 PM
282977 Re: ASM Recap iblong22000 6/10/2009 3:42:46 PM
282980 Re: ASM Recap sourberry 6/10/2009 3:51:23 PM
283034 Re: ASM Recap Winvestor 2 6/10/2009 11:14:23 PM
About Us  •  Members Directory  •  Help  •  Contact Us
Not a member yet? What are you waiting for? Join Now
Want to contribute? Support InvestorVillage by donating
© 2003-2010 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by Xignite.


Loading...